Samchundang Pharm has issued an official statement regarding recent media reports, stepping up to alleviate shareholders' concerns.

Through a notice, Samchundang Pharm stated that it has not received any investigation initiation notice or formal request for document submission from regulatory authorities, including the Financial Supervisory Service (FSS). The company's policy is to transparently and faithfully cooperate with investigation procedures if requested by relevant authorities in the future.

Regarding the reports of its designation as an unfair disclosure entity, the company explained the specific background. According to the company, the cause was its failure to fulfill its fair disclosure obligation by distributing the performance results related to Ilyria biosimilar (SCD411) for the Canadian market via a press release without going through the formal disclosure procedure. Samchundang Pharm clarified that this matter is a separate issue unrelated to the U.S. and European contract issues mentioned together in the media.

A company official stated that they are humbly accepting the Korea Exchange's disciplinary action and are currently strengthening their disclosure management system by overhaul internal regulations and related procedures to prevent similar cases from recurring. The official added that core business and operational activities are currently proceeding normally without disruption, and that the company will continue to enhance shareholder value and meet the trust of stakeholders through transparent management and faithful communication.

[This article was written with the assistance of AI. Investment decisions are the responsibility of the individual investor, and stock price volatility may increase depending on market conditions.]